AEON Biopharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AEON research report →
Price Chart
About the company
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis.
- CEO
- Robert Bancroft
- IPO
- 2023
- Employees
- 8
- HQ
- Irvine, CA, US
Get TickerSpark's AI analysis on AEON
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $12.79M
- P/E
- -0.08
- Fwd P/E
- 1.76
- PEG
- 0.00
- P/S
- 0.00
- P/B
- -0.95
- EV/EBITDA
- -0.47
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 204.18%
- ROIC
- 1699.74%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-12,803,000
- Net Income
- $-39,222,000-193.4%
- EPS
- $-3.95-105.1%
- OCF Growth
- +14.7%
- FCF Growth
- +14.7%
- 52W High
- $1.45
- 52W Low
- $0.18
- 50D MA
- $0.26
- 200D MA
- $0.76
- Beta
- 0.69
- RSI (14)
- 54
- Avg Volume
- 8.64M
No earnings-call transcripts are available for AEON yet.
- Free Float
- 27.4%
- Shares Outstanding
- 44.16M
- Float Shares
- 12.10M
of shares held by institutions
23 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Dauntless Investment Group, LLC | 12.49M | ▲ 9.96M |
| Vanguard Group Inc | 100.33K | ▲ 1.76K |
| Geode Capital Management, LLC | 95.31K | ▲ 8.25K |
| Vanguard Capital Management LLC | 90.53K | 0 |
| Blue Owl Capital Holdings LP | 42.35K | 0 |
| Formidable Asset Management, LLC | 20.02K | 0 |
| Stonex Group Inc. | 18.95K | ▲ 18.95K |
| Vanguard Fiduciary Trust Co | 13.71K | ▼ 989 |
| Beacon Wealthcare LLC | 12.86K | ▲ 12.86K |
| Lpl Financial LLC | 11.51K | 0 |
| Citigroup Inc | 7.32K | ▲ 6.57K |
| Ubs Group AG | 5.06K | ▲ 880 |
Held by 8 ETFs
Biggest fund positions in AEON by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 19, 26 | LYNCH TIMOTHY P | buy | 1,150,000 |
| Aug 19, 26 | LYNCH TIMOTHY P | other | 0 |
| Aug 19, 26 | LYNCH TIMOTHY P | other | 1,000,000 |
| Jul 15, 26 | LYNCH TIMOTHY P | other | 3,000,000 |
| Jul 15, 26 | LYNCH TIMOTHY P | other | 3,000,000 |
| Jun 17, 26 | Thunen Shelley B | other | 222,684 |
| Jun 17, 26 | PALMISANO ROBERT J | other | 222,684 |
| Jun 17, 26 | Forth Marc | other | 222,684 |
| Jun 17, 26 | FISCHER JOST | other | 222,684 |
| Jun 17, 26 | Carter Eric G | other | 222,684 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AEON coverage
Recent articles, reports, and earnings notes.
No research on AEON yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AEON report →AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
globenewswire.com · Sep 30
AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®
globenewswire.com · Sep 9
AEON Biopharma to Participate in Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference
globenewswire.com · Aug 31
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer
globenewswire.com · Aug 24
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®
globenewswire.com · Aug 19
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Aug 12
AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
globenewswire.com · Aug 3
Bitget Launchpool adds AEON (AEON) with 1.1M in Token Rewards
globenewswire.com · Jul 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.